查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011268

癌症治療及輔助治療藥物市場：2026-2032年全球市場預測（依藥物類型、給藥途徑、作用機轉、適應症及通路分類）

Cancer Therapeutics & Supportive Care Drugs Market by Drug Type, Route Of Administration, Mechanism Of Action, Indication, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症治療和支持護理市場價值將達到 3,713.8 億美元，到 2026 年將成長至 4,082 億美元，到 2032 年將達到 7,624.2 億美元，複合年成長率為 10.82%。

主要市場統計數據
基準年 2025 3713.8億美元
預計年份：2026年 4082億美元
預測年份 2032 7624.2億美元
複合年成長率 (%) 10.82%

從策略角度探討臨床、監管和商業性因素的融合如何重塑現代腫瘤學中癌症治療和支持性護理的提供方式。

在癌症治療和支持性護理領域，科學創新、不斷發展的臨床實踐和不斷變化的商業性模式相互交織，需要一個清晰的策略框架來全面應對這些因素。本導言將相關人員置於現代癌症治療的關鍵要素——靶向分子治療、免疫療法以及以患者為中心的支持性護理——的交匯點。

對從根本上改變腫瘤治療模式和支持性護理方法的關鍵科學、臨床和商業性轉折點進行權威分析。

在腫瘤學領域，改變正在發生，重塑治療方法的研發、應用和報銷模式。首先，標靶生技藥品和小分子藥物擴大與精準的伴隨診斷相結合，推動著治療方法從單一模式轉向分層治療路徑的轉變。同時，藥物偶聯物和重組抗體的進步正在改變藥物的安全性，並使以往需要住院治療的病例也能實現門診給藥，從而重塑醫療服務模式和成本結構。

對 2025 年定價政策環境將如何重新定義癌症藥物和支持性治療的供應鏈韌性、籌資策略和定價框架進行實際評估。

美國將於2025年推出一項新的定價政策，這將進一步增加全球供應鏈、籌資策略以及涵蓋所有癌症藥物和輔助治療產品的定價的複雜性。製造商和經銷商將面臨透過國際樞紐採購某些活性成分和特殊輔料成本增加的問題，同時，額外的物流費用和合規義務也迫使他們重新評估採購地點和供應商協議。

從詳細的細分觀點治療領域、給藥途徑、作用機制、適應症和分銷管道與策略決策聯繫起來。

嚴謹的細分框架揭示了不同治療方法和支持性護理、給藥途徑、作用機制、適應症和通路的差異化趨勢，這些趨勢共同塑造了策略和投資重點。從藥物類型來看，支持性護理藥物和治療性藥物之間的區別有助於明確臨床資源的分配：支持性護理藥物包括鎮痛藥、止吐藥、促紅血球生成素和造血生長因子，這些藥物直接針對症狀控制和治療耐受性。而治療性藥物則包括抗體藥物複合體、細胞毒性化學療法、荷爾蒙、單株抗體和小分子抑制劑，這些藥物追求直接抗癌活性或分子層面的精準標靶作用。

一項評估考慮了美洲、歐洲、中東和非洲以及亞太地區監管、償還和實施變數的地域細微差別，從而製定區域策略。

區域趨勢對監管路徑、報銷標準和臨床引入模式有顯著影響，因此需要製定尊重當地醫療保健系統結構的、針對特定區域的最佳化策略。在美洲，成熟的法規環境和先進的支付方基礎設施促進了高價值療法的快速引入，同時，強力的衛生經濟學證據和基於結果的合約對於確保其被納入處方藥目錄至關重要。這種環境促使人們更加關注真實世界數據（REW）的生成、病患支持計畫以及整合式照護路徑，以在住院和門診環境中展現其價值。

企業層面的策略挑戰凸顯了創新、夥伴關係、業務永續營運和證據生成在確定腫瘤學和支持性護理領域的競爭優勢的重要性。

生物製藥和專科醫療保健公司之間的競爭格局體現了研發管線創新、夥伴關係策略以及商業化和病患支援能力之間的平衡。主要企業正在增加對抗體藥物複合體(ADC) 和雙特異性抗體等差異化治療方法的投入，同時也在投資於能夠提高耐受性和依從性的輔助治療產品，從而為臨床醫生和支付方創造全面的價值提案。

一項旨在將臨床創新、業務永續營運和基於價值的商業化整合到腫瘤醫療保健服務中的實用策略舉措，面向行業領導者。

行業領導企業應推動一系列綜合舉措，將科學創新與實際應用相結合，以確保其在臨床環境中得到應用並獲得支付方的認可。首先，應優先開發將治療方案與支持性護理解決方案相結合的聯合策略，透過展現全面的患者獲益和更高的耐受性，增強對支付方和臨床醫生的價值主張。其次，應投資於分散式照護模式和支持口服和皮下給藥的數位化用藥依從性平台，從而減少對資源密集型輸液中心的依賴，並提高病患的便利性。

我們透過透明、多方面的調查方法，結合臨床文獻綜述、相關人員訪談、監管環境分析和供應鏈分析，得出切實可行的見解。

本研究採用混合方法，旨在將質性研​​究結果與結構化證據綜述、監管圖譜和相關人員訪談結合。該調查方法整合了對同行評審的臨床文獻和已發布的監管文件的全面審查，以及對臨床醫生、保險公司和配銷通路專家的深入訪談，從而將臨床效用、安全性以及各治療和支持性護理領域的准入障礙置於具體情境中進行分析。

簡潔而全面的結論將治療創新、支持性護理整合和營運韌性作為未來腫瘤學策略的支柱。

總之，創新治療方法與先進支持治療的相互作用正在重塑腫瘤治療實踐，這需要臨床、商業和營運等各個方面進行整合應對。精準標靶治療和不斷發展的作用機制拓展了治療的可能性，而增強的支持治療能力則使得更積極且耐受性更好的治療方法成為可能，從而優先考慮患者的生活品質。同時，諸如關稅造成的供應鏈挑戰等外部壓力，要求進行策略性的營運調整，以確保治療的可及性和可負擔性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：癌症治療藥物和支持治療藥物市場（按藥物類型分類）

  • 支持性護理
    • 止痛藥
    • 止吐藥
    • 紅血球造血促效劑
    • 造血生長因子
  • 治療藥物
    • 抗體藥物複合體
    • 細胞毒性化學療法
    • 荷爾蒙藥物
    • 單株抗體
    • 小分子抑制劑

第9章：癌症治療與支持治療藥物市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下

第10章：按作用機制分類的癌症治療和支持治療藥物市場

  • 查核點抑制劑
  • 免疫調節藥物
  • 單株抗體
  • 蛋白酶體抑制劑
  • 蛋白酪氨酸激酶抑制劑

第11章 癌症治療與支持治療藥物市場：依適應症分類

  • 乳癌
  • 結腸癌
  • 白血病
  • 肺癌
  • 淋巴瘤

第12章 癌症治療與支持治療藥物市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第13章 癌症治療與支持治療藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 癌症治療與支持治療藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 癌症治療與支持性治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國癌症治療與支持治療藥物市場

第17章：中國癌症治療及輔助治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Helsinn Healthcare SA
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4316E4E89554

The Cancer Therapeutics & Supportive Care Drugs Market was valued at USD 371.38 billion in 2025 and is projected to grow to USD 408.20 billion in 2026, with a CAGR of 10.82%, reaching USD 762.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 371.38 billion
Estimated Year [2026] USD 408.20 billion
Forecast Year [2032] USD 762.42 billion
CAGR (%) 10.82%

A strategic orientation to the converging clinical, regulatory, and commercial forces reshaping cancer therapeutics and supportive care delivery in modern oncology

The cancer therapeutics and supportive care landscape is experiencing a confluence of scientific innovation, evolving clinical practice, and shifting commercial paradigms that demand a concise strategic framing. This introduction situates stakeholders at the intersection of targeted molecular therapies, immune-based approaches, and an intensified emphasis on patient-centric supportive care that together define contemporary oncology management.

In clinical settings, the rise of precision medicine has reoriented treatment selection toward biomarker-driven therapeutics while supportive care modalities have refined symptom control, enabling patients to tolerate intensive regimens and maintain quality of life. Concurrently, payers and health systems increasingly scrutinize value propositions across therapeutic and supportive pathways, prompting manufacturers and providers to demonstrate real-world effectiveness, safety, and adherence outcomes.

Against this backdrop, the report synthesizes cross-functional evidence to help executives, clinicians, and policy leaders make informed choices. By integrating clinical trends, regulatory signals, and commercial dynamics, the introduction clarifies why coordinated strategies across therapeutics and supportive care are essential for sustainable patient benefit and organizational success.

Definitive analysis of the major scientific, clinical, and commercial inflection points driving fundamental changes in oncology treatment paradigms and supportive care approaches

The oncology landscape is undergoing transformative shifts that reconfigure how therapies are developed, delivered, and reimbursed. First, targeted biologics and small molecule agents are increasingly paired with precise companion diagnostics, driving a move away from one-size-fits-all regimens toward stratified treatment pathways. At the same time, advances in drug conjugates and engineered antibodies are altering safety profiles and enabling outpatient administration where once inpatient care was necessary, thereby reshaping care settings and cost structures.

Second, supportive care has emerged as a strategic complement to therapeutics rather than a mere adjunct. Improved antiemetics, analgesics, erythropoiesis stimulating agents, and hematopoietic growth factors now integrate into treatment protocols early, sustaining adherence and enabling combination strategies that were previously untenable. Consequently, clinical teams and payers place greater emphasis on total cost of care and quality-of-life metrics, elevating supportive care interventions as measurable contributors to outcomes.

Third, mechanistic diversification-spanning checkpoint inhibitors, immunomodulators, proteasome inhibitors, and tyrosine kinase inhibitors-creates a complex therapeutic mosaic that challenges formulary management and clinical guidelines. This complexity intersects with evolving routes of administration, including oral and subcutaneous formulations, which enhance convenience but necessitate new adherence support models and remote monitoring capabilities. Together, these shifts compel manufacturers and providers to invest in integrated care models, patient support programs, and evidence generation that demonstrates incremental clinical and economic value.

Practical evaluation of how the 2025 tariff environment redefines supply chain resilience, procurement strategy, and pricing frameworks across oncology therapeutics and supportive care

The introduction of new tariff policies in the United States in 2025 has introduced additional layers of complexity for global supply chains, procurement strategies, and pricing decisions across cancer therapeutics and supportive care portfolios. Manufacturers and distributors face increased input costs for certain active pharmaceutical ingredients and specialized excipients that transit international nodes, while logistics surcharges and compliance obligations have prompted re-evaluation of sourcing footprints and vendor agreements.

As a consequence, stakeholders are recalibrating procurement cadence, favoring longer-term contracts with tiered pricing mechanisms and greater reliance on near-shore or domestic manufacturing where feasible to mitigate exposure to external tariff volatility. Regulatory teams are also engaging earlier with customs and trade counsel to optimize tariff classifications, explore duty drawback opportunities, and ensure documentation aligns with preferential trade rules when applicable. These practical adjustments are not merely operational but influence product lifecycle economics, the prioritization of development programs, and commercial access strategies.

Importantly, health system purchasers and specialty pharmacies are responding by intensifying competitive tender processes and seeking enhanced total-cost-of-care analyses to inform contracting. Manufacturers, in turn, must provide transparent cost structures and innovative contracting models that reflect the new tariff environment while safeguarding patient access and continuity of supply. In this shifting landscape, proactive scenario planning, diversified supply chains, and contractual flexibility become essential risk management practices.

An in-depth segmentation-driven perspective that connects therapeutic classes, administration routes, mechanisms of action, indications, and distribution channels to strategic decision-making

A rigorous segmentation framework reveals differentiated dynamics across therapeutic and support modalities, routes of administration, mechanisms of action, indications, and distribution pathways that together shape strategy and investment priorities. When viewed through the lens of drug type, the distinction between Supportive Care and Therapeutics clarifies allocation of clinical resources: Supportive Care encompasses Analgesics, Antiemetics, Erythropoiesis Stimulating Agents, and Hematopoietic Growth Factors that directly target symptom control and treatment tolerability, whereas Therapeutics comprises Antibody Drug Conjugates, Cytotoxic Chemotherapy, Hormonal Agents, Monoclonal Antibodies, and Small Molecule Inhibitors that drive direct anti-cancer activity and molecular precision.

Transitioning to route of administration considerations, Intramuscular, Intravenous, Oral, and Subcutaneous delivery modalities each impose distinct clinical workflow requirements and patient adherence implications. Oral and subcutaneous options create opportunities for decentralization and self-administration, which in turn shift the burden toward outpatient care coordination and remote monitoring, while intravenous and intramuscular routes maintain demand for infusion centers and trained clinical staff. These delivery choices influence formulary placement, reimbursement negotiation, and the design of patient support programs.

Mechanism of action segmentation highlights therapeutic differentiation among Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, Proteasome Inhibitors, and Tyrosine Kinase Inhibitors, each carrying unique safety considerations, monitoring requirements, and combination potential. For instance, immune-related adverse events tied to checkpoint inhibitors necessitate integrated toxicity management protocols that implicate supportive care resources, while targeted inhibitors often require biomarker-driven patient selection and adherence support. Therefore, developers must align evidence generation with mechanism-specific endpoints and real-world safety surveillance.

Indication-based segmentation-covering Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, and Lymphoma-demonstrates heterogeneity in clinical pathways, standard-of-care backbones, and unmet needs. Each indication presents distinct lines of therapy, payer expectations, and patient advocacy engagement models that influence trial design and commercialization tactics. Finally, distribution channel segmentation, incorporating Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Pharmacies, maps to differing inventory management, cold-chain logistics, and reimbursement reconciliation practices, all of which require tailored commercial strategies to ensure availability and adherence-support services across care settings.

Collectively, these segments inform targeted commercial playbooks, clinical trial inclusion criteria, and post-approval evidence strategies that reconcile therapeutic innovation with pragmatic delivery and access considerations.

A geographically nuanced evaluation of regulatory, reimbursement, and adoption variables across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape regional strategies

Regional dynamics exert pronounced influence on regulatory pathways, reimbursement norms, and clinical adoption patterns, requiring geographically tailored strategies that respect local health system architectures. In the Americas, a mature regulatory environment and advanced payer infrastructures favor rapid adoption of high-value therapeutics but also compel robust health economic evidence and outcomes-based contracting to secure formulary positioning. This environment drives emphasis on real-world evidence generation, patient assistance programs, and integrated care pathways to demonstrate value across inpatient and outpatient settings.

By contrast, Europe, Middle East & Africa presents a mosaic of regulatory agencies, reimbursement thresholds, and healthcare delivery models that necessitate flexible submission strategies and differentiated pricing approaches. Centralized regulatory processes coexist with country-level health technology assessment agencies, reinforcing the need for parallel health economic dossiers and adaptive market access plans that account for national variations in clinical practice and procurement mechanisms. Meanwhile, capacity constraints in certain markets elevate the importance of supportive care solutions that reduce hospitalization and facilitate outpatient management.

In the Asia-Pacific region, fast-growing innovation hubs and expanding clinical research ecosystems coexist with variable reimbursement environments and differing standards of care. Local manufacturing capacity, preferential procurement policies, and evolving regulatory frameworks influence go-to-market timing and partnership models. Across all regions, cultural factors and patient expectations shape adherence behaviors and acceptance of novel administration routes, so successful market strategies integrate regional nuances in clinician engagement, patient education, and distribution infrastructure planning. Ultimately, regional insight enables prioritized resource allocation and nuanced stakeholder engagement to accelerate clinical uptake and sustainable access.

Strategic company-level imperatives highlighting how innovation, partnerships, operational resilience, and evidence generation determine competitive advantage in oncology and supportive care

Competitive dynamics among biopharmaceutical and specialty care companies reflect a balance between pipeline innovation, partnership strategies, and capabilities in commercialization and patient support. Leading developers increasingly pursue differentiated modalities such as antibody drug conjugates and bispecific constructs, while also investing in supportive care assets that enhance tolerability and adherence, thereby creating bundled value propositions for clinicians and payers.

Strategic alliances and licensing agreements remain pivotal for rapid access to complementary technologies, with companies leveraging partnerships to fill gaps across manufacturing scale, biomarker development, and digital adherence tools. Concurrently, specialty pharmacies and hospital systems are evolving into strategic allies, as their distribution expertise and integrated care models determine on-the-ground uptake. To compete effectively, organizations must align R&D portfolios with clear pathways to clinical differentiation, demonstrate capability in evidence generation for both therapeutics and supportive care, and develop scalable commercialization models that account for complex reimbursement landscapes.

Moreover, corporate agility in supply chain optimization and tariff mitigation will distinguish firms that can maintain consistent supply and predictable pricing. Companies that prioritize post-market surveillance and real-world data analytics will gain credibility with clinicians and payers, enhancing long-term uptake. In sum, successful companies will blend scientific differentiation with operational excellence and stakeholder-centric commercial approaches.

Actionable strategic initiatives for industry leaders to integrate clinical innovation, operational resilience, and value-based commercialization in oncology care delivery

Industry leaders should pursue an integrated set of actions that align scientific innovation with pragmatic execution to secure clinical adoption and payer acceptance. First, prioritize the development of combination strategies that link therapeutics with supportive care solutions to demonstrate holistic patient benefit and improved tolerability, thereby strengthening value narratives for payers and clinicians. Second, invest in decentralized care models and digital adherence platforms that support oral and subcutaneous administration, enabling shifts away from resource-intensive infusion centers and improving patient convenience.

Third, enhance supply chain resilience through geographic diversification of manufacturing, strategic inventory buffering, and tariff-aware procurement practices that reduce exposure to trade disruptions. Fourth, design evidence generation plans that extend beyond randomized controlled trials to include real-world effectiveness, patient-reported outcomes, and health economic assessments tailored to regional reimbursement requirements. Fifth, cultivate partnerships with specialty pharmacies, hospital networks, and patient advocacy organizations to streamline distribution, adherence support, and education efforts that accelerate uptake across indications.

Finally, adopt outcome-oriented commercial agreements where feasible, aligning pricing and reimbursement to real-world performance metrics. By combining these priorities, industry leaders can reduce access friction, improve patient outcomes, and create defensible commercial pathways that reflect both scientific value and operational sustainability.

Transparent, multi-source research methodology combining clinical literature review, stakeholder interviews, regulatory mapping, and supply chain analysis to support actionable insights

This research synthesis employs a mixed-methods approach designed to harmonize qualitative insights with structured evidence review, regulatory mapping, and stakeholder interviews. The methodology integrates a comprehensive review of peer-reviewed clinical literature and public regulatory filings with in-depth interviews of clinicians, payers, and distribution channel experts to contextualize clinical utility, safety profiles, and access barriers across therapeutic and supportive care segments.

Data triangulation underpins findings: clinical evidence is cross-referenced with guideline updates, pharmacovigilance reports, and payer policy documents to ensure robust interpretation of therapeutic impacts and supportive care roles. Supply chain and commercial dynamics are analyzed through vendor and manufacturer disclosures, trade policy documents, and publicly available logistics frameworks to assess practical implications of tariffs and procurement trends. Regional insights derive from country-level regulatory publications and stakeholder input that capture local practice patterns and reimbursement decision-making.

Finally, the methodology emphasizes transparency and reproducibility. Assumptions underlying qualitative judgments are documented, interview protocols and aggregation methods are disclosed, and limitations are explicitly stated to help readers interpret the evidence base responsibly. This rigorous approach enables stakeholders to apply the report's conclusions with confidence while adapting strategies to their specific organizational contexts.

A concise overarching conclusion that synthesizes therapeutic innovation, supportive care integration, and operational resilience as the pillars of future oncology strategy

In conclusion, the interplay between innovative therapeutics and refined supportive care is reshaping oncology practice in ways that demand integrated clinical, commercial, and operational responses. Precision-targeted agents and evolving mechanisms of action are expanding therapeutic possibilities, while enhanced supportive care capabilities are enabling more aggressive yet tolerable regimens that prioritize patient quality of life. At the same time, external pressures-such as tariff-driven supply chain considerations-require strategic operational adaptations to preserve access and affordability.

Moving forward, stakeholders who align product development with pragmatic delivery models, prioritize evidence generation that addresses both clinical outcomes and economic value, and invest in partnerships that extend distribution and adherence capabilities will be best positioned to succeed. The synthesis presented here equips decision-makers with a cohesive framework to navigate complexity, optimize cross-functional investments, and deliver measurable improvements in patient-centered care. Ultimately, coordinated strategies that bridge therapeutic innovation and supportive care execution will define future standards of oncology delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Therapeutics & Supportive Care Drugs Market, by Drug Type

  • 8.1. Supportive Care
    • 8.1.1. Analgesics
    • 8.1.2. Antiemetics
    • 8.1.3. Erythropoiesis Stimulating Agents
    • 8.1.4. Hematopoietic Growth Factors
  • 8.2. Therapeutics
    • 8.2.1. Antibody Drug Conjugates
    • 8.2.2. Cytotoxic Chemotherapy
    • 8.2.3. Hormonal Agents
    • 8.2.4. Monoclonal Antibodies
    • 8.2.5. Small Molecule Inhibitors

9. Cancer Therapeutics & Supportive Care Drugs Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Cancer Therapeutics & Supportive Care Drugs Market, by Mechanism Of Action

  • 10.1. Checkpoint Inhibitors
  • 10.2. Immunomodulators
  • 10.3. Monoclonal Antibodies
  • 10.4. Proteasome Inhibitors
  • 10.5. Tyrosine Kinase Inhibitors

11. Cancer Therapeutics & Supportive Care Drugs Market, by Indication

  • 11.1. Breast Cancer
  • 11.2. Colorectal Cancer
  • 11.3. Leukemia
  • 11.4. Lung Cancer
  • 11.5. Lymphoma

12. Cancer Therapeutics & Supportive Care Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies
  • 12.4. Specialty Pharmacies

13. Cancer Therapeutics & Supportive Care Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Therapeutics & Supportive Care Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Therapeutics & Supportive Care Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cancer Therapeutics & Supportive Care Drugs Market

17. China Cancer Therapeutics & Supportive Care Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. Bristol-Myers Squibb Company
  • 18.9. Cipla Limited
  • 18.10. Dr. Reddy's Laboratories Ltd.
  • 18.11. Eli Lilly and Company
  • 18.12. F. Hoffmann-La Roche Ltd
  • 18.13. Gilead Sciences, Inc.
  • 18.14. GlaxoSmithKline plc
  • 18.15. Helsinn Healthcare SA
  • 18.16. Johnson & Johnson Services, Inc.
  • 18.17. Lupin Limited
  • 18.18. Merck & Co., Inc.
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Sanofi S.A.
  • 18.22. Sun Pharmaceutical Industries Limited
  • 18.23. Takeda Pharmaceutical Company Limited
  • 18.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CYTOTOXIC CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY HORMONAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY HORMONAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 208. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)